Weight-Loss drug may boost heart procedure success in AF patients
NCT ID NCT07389941
First seen Feb 05, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This study tests whether taking semaglutide (a weight-loss drug) before a standard heart procedure called catheter ablation helps people with obesity and atrial fibrillation stay free from abnormal heart rhythms for a year. About 240 adults with a BMI of 30 or higher (or 28 with related health issues) will receive either semaglutide or usual care before their first ablation. The goal is to see if pre-treatment improves long-term heart rhythm control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.